mdc-ANG / Teva, MedinCell - LARVOL DELTA

MedinCell Publishes Its First-half 2020/2021 Financial Results (april - September 2020): Operating Expenses and Portfolio Development in Line With Expectations (Businesswire) - "November 2020 (post-closing) – Phase 3 pivotal efficacy study completed in the United States for the mdc-IRM program, an experimental long-acting subcutaneous injectable treatment of risperidone for schizophrenia. Teva Pharmaceuticals, which funds and oversees the development of the program, expects to have the trial readout during the first quarter of 2021....Progress in the regulatory development of two other antipsychotics: mdc-TJK in Phase 1 and mdc-ANG in preclinical development....The first-in-human study for the investigational long-acting injectable antipsychotic mdc-TJK has started in Q4 2019. The results of this study, expected during 2021, will inform future development."

Clinical data • P3 data • Trial completion • CNS Disorders • Schizophrenia

MedinCell Provides an Update on Its Product Portfolio, Following the FDA Acceptance of New Drug Application for the Product mdc‑IRM (GlobeNewswire) - "mdc-IRM...The new drug application is under review by the FDA. The commercial launch in the U.S. could start in 2022; mdc-ANG...Ongoing preclinical work could lead to the start of clinical activities before the end of 2021."

Launch US • New trial • CNS Disorders • Schizophrenia